AAV2 Serotype
First AAV serotype discovered and most extensively characterized. Gold standard for AAV research with broad tissue tropism. Foundation for most engineered AAV variants.
| Tropism | Broad - CNS, liver, muscle, retina, lung |
|---|
Characteristics
Most studied AAV serotype. Uses HSPG as primary receptor. Broad tissue tropism but modest transduction efficiency. High pre-existing immunity (~60-80% seropositive in humans). Efficient transduction of neurons, photoreceptors, hepatocytes. Slow onset of transgene expression (2-4 weeks).
Applications
Retinal gene therapy (Luxturna - FDA approved for RPE65-associated retinal dystrophy). Hemophilia B (early trials). Parkinson's disease (AADC deficiency). CNS research tool. Proof-of-concept studies. Foundation for capsid engineering.
Sequence1 bp
Sign in to view the full sequence.
Sign inReferences
- 1.Russell et al. (2017). Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy. Lancet — Russell 2017 Luxturna
